A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS. We are a biotechnology company focused on developing personalized immune therapies for cancer. We have developed a platform technology, DCVax®, which uses activated dendritic cells to mobilize a patient’s own immune system to attack their cancer. Our lead product candidate, DCVax®-L, is designed to treat solid tumor cancers in which the tumor can be surgically removed. We have completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM), published the results in the JAMA Oncology peer reviewed journal, and on December 20, 2023 we submitted a Marketing Authorization Application (MAA) for commercial approval in the U.K. We plan to conduct clinical trials of DCVax-L for other solid tumor cancers in the future, when resources permit. Our second product candidate, DCVax®-Direct, is designed to treat inoperable solid tumors.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 937K | - | - | - | - | - |
| Net Income | -91M | -85M | -64M | -105M | 179M | -530M |
| EPS | $-0.06 | $-0.07 | $-0.06 | $-0.10 | $-0.06 | $-0.73 |
| Free Cash Flow | -50M | -57M | -54M | -53M | -38M | -32M |
| ROIC | -167.5% | -196.6% | -157.4% | -169.4% | -131.2% | -208.0% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.43 | -0.43 | -0.29 | -0.32 | -0.05 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -65M | -67M | -56M | -67M | -53M | -87M |
| Operating Margin | -6927.3% | - | - | - | - | - |
| ROE | 0.0% | - | - | - | - | - |
| Shares Outstanding | 1,541M | 1,217M | 1,073M | 1,050M | 948M | 726M |
NORTHWEST BIOTHERAPEUTICS INC passes 0 of 9 quality checks, indicating weak fundamentals.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) has a 5-year average return on invested capital (ROIC) of -163.7%. This is below average and may indicate limited pricing power.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) has a market capitalization of $310M. It is classified as a small-cap stock.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) does not currently pay a regular dividend.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) generated $-57 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) reported earnings per share (EPS) of $-0.07 in its most recent fiscal year.
The Ledger Terminal provides 15 years of financial data for NORTHWEST BIOTHERAPEUTICS INC (NWBO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
NORTHWEST BIOTHERAPEUTICS INC (NWBO) has a book value per share of $-0.08, based on its most recent annual SEC filing.